Advancements in Cancer Cachexia Management and Beyond: A Spotlight on Industry Collaborations and Breakthroughs

According to analysts at Vantage Market Research, the Cancer Cachexia market is anticipated to achieve USD 4.03 Billion by 2032 with a CAGR of 5%.

Veru Partners with Eli Lilly for Phase 3 ENABLAR-2 Trial

Veru Inc., an oncology biopharmaceutical company, announced a clinical trial collaboration with Eli Lilly to evaluate enobosarm in combination with Verzenio® (abemaciclib) in a Phase 3 trial for AR+ER+HER2- metastatic breast cancer, set to begin in Q1 2022. The ENABLAR-2 trial will assess this combination's efficacy and safety, potentially offering a second-line therapy option. Enobosarm, an oral selective androgen receptor agonist, has shown promise in muscle building and fat reduction, addressing key cancer cachexia symptoms. Preclinical studies demonstrated significant anti-tumor activity when combined with a CDK4/6 inhibitor. Veru will conduct the trial with Lilly supplying Verzenio®, involving 186 patients across 35 U.S. sites. Enobosarm's favorable side effect profile and extensive clinical experience, including 25 studies with over 1,450 subjects, highlight its potential in cancer cachexia management.

ARTHEx Biotech's Breakthrough Drug Delivery Platform

ARTHEx Biotech introduces a pioneering drug delivery platform designed to target microRNAs (miRNAs) in challenging diseases like Myotonic Dystrophy Type 1 (DM1). With a focus on tissue-enriched delivery of investigational oligonucleotides, this platform offers hope for patients with unmet medical needs, promising advancements in targeted therapies for various conditions including cancer cachexia and osteoarthritis.

Bristol Myers Squibb's Data Presentation at ASCO & EHA

Bristol Myers Squibb (NYSE: BMY) is set to unveil data from over 130 studies spanning 25 cancer types and serious blood disorders at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. Such presentations will highlight the company's commitment to advancing research across various oncology and hematology domains, showcasing pivotal studies, long-term survival data, and emerging scientific insights.

These collaborations and research initiatives underscore the pharmaceutical industry's dedication to developing innovative treatments and improving patient outcomes across a spectrum of diseases.